Merck Serono to lose Swiss HQ and 500 people
This article was originally published in Scrip
Merck KGaA will close the Geneva headquarters of its pharmaceutical business, Merck Serono, and cut 500 jobs, according to cost-saving plans announced today. "It just wasn't working financially to have two pharmaceutical headquarters and R&D hubs in Europe," a spokesperson told Scrip. "The whole point of the efficiency programme is to make the company more profitable and viable for the future."
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.